FDA approves olaparib with abiraterone and prednisone
On May 31, 2023, the Food and Drug Administration approved olaparib (Lynparza, AstraZeneca Pharmaceuticals LP) with abiraterone and prednisone (or prednisolone) for adult patients with...
LYNPARZA® (olaparib) demonstrated clinically meaningful …
2024年12月11日 · At a median follow-up of 6.1 years in eligible patients, who had completed local treatment and standard neoadjuvant or adjuvant chemotherapy, results showed LYNPARZA reduced the risk of death by...
6-Year Data Sustain Adjuvant Olaparib Benefit in BRCA1/2+, HER2 …
2024年12月11日 · Six-year results continued to show the clinically meaningful efficacy of adjuvant olaparib vs placebo in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer, according to findings from the third pre-specified analysis of the phase 3 OlympiA trial (NCT02032823). 1. The analysis occurred at a median follow-up of 6.1 years (max, 9.6 years) and 2.6 years since the ...
FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and
2023年6月1日 · AboutLYNPARZA ® (olaparib) LYNPARZA is a first-in-class PARP inhibitor and the first targeted treatment to potentially exploit DNA damage response (DDR) pathway deficiencies, such as BRCA mutations, to preferentially kill cancer cells. Inhibition of PARP with LYNPARZA leads to the trapping of PARP bound to DNA single-strand breaks, stalling of ...
Olaparib: Drug to treat inherited cancers offered on NHS in ... - BBC
2023年4月6日 · The drug olaparib is designed to treat specific cancers linked to faulty versions of genes known as BRCAs. Some 800 people in total will be eligible for the treatment.
LYNPARZA® (olaparib) Reduced Risk of Death by 32% in Patients …
2022年3月16日 · OlympiA has now shown that olaparib not only reduced the risk of recurrence, but also improved overall survival for women with high risk early-stage breast cancer and a BRCA1/2 mutation and is an exciting demonstration of the benefits of targeting the specific biology of disease for these women.”
Merck-AstraZeneca breast cancer drug Lynparza improves long …
1 天前 · Lynparza (olaparib), a product of Fortune 500 pharmaceutical firm Merck and Fortune 500 Europe company AstraZeneca, showed meaningful improvements in overall survival in people with germline BRCA ...
Olaparib - latest research news and features - Medical Xpress
Olaparib (Lynparza), a targeted cancer drug, has been approved for hundreds of patients with certain breast cancers and prostate cancers in England.
Olaparib Protects Patients From High-Risk Cancer Recurrences
2024年12月12日 · The benefit of the PARP inhibitor in patients with germline BRCA pathogenic variants remains evident 10 years after the first patient in the phase 3 OlympiA trial was enrolled.
Olaparib provides survival benefits for high-risk BRCA-positive …
2024年12月11日 · Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a...